ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (01541.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 1.40B

MomentumView details →

1D Return

+0.29%

YTD Return

−41.68%

RSI (14)

46.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 1.40B

RSI (14)

46.7

MomentumView details →

1D Return

+0.29%

YTD Return

−41.68%

ProfitabilityView details →

Gross Margin

97.00%

Net Margin

−192.96%

EBITDA Margin

−182.86%

ROE (TTM)

−84.61%

ROA (TTM)

−51.40%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+4008.35%

EPS YoY

+35.34%

FCF YoY

+66.41%

Revenue CAGR 3Y

+197.82%

EPS CAGR 3Y

+39.29%

EBITDA YoY

+27.78%

EarningsView details →

EPS (Actual)

−HKD 0.44

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.58x

Current Ratio

2.66x

Quick Ratio

2.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

274.41M

Net Income (TTM)

−529.50M

Op. CF (TTM)

−208.55M

Next earningsMar 30, 2027 →

Latest newsMore news →

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first patient has been dosed in its Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced hepatocellular carcinoma.8d ago

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced its interim results for the six months ended June 30, with revenue of 25.42 million RMB, down 33.1% year-on-year, net loss widening to 164 million RMB, loss per share of 0.38 RMB, and no dividend.9d ago

Similar companies

Alto Neuroscience, Inc.ANRO Replimune Group, Inc.REPL Odyssey Therapeutics, Inc.ODTX Zhaoke Ophthalmology Limited06622.HK Omeros CorporationOMER Immatics N.V.IMTX Find similar companies →

Latest newsMore news →

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first patient has been dosed in its Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced hepatocellular carcinoma.8d ago ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced its interim results for the six months ended June 30, with revenue of 25.42 million RMB, down 33.1% year-on-year, net loss widening to 164 million RMB, loss per share of 0.38 RMB, and no dividend.9d ago